• BUSINESS
    • FINANCE
    • LEGAL
    • RETAIL & CONSUMER
    • AUTOS & TRANSPORTATION
    • HEALTHCARE & PHARMACEUTICALS
    • MEDIA & TELECOM
    • AEROSPACE AND DEFENSE
    • ENERGY
  • MARKETS
    • EUROPEAN MARKETS
    • ASIAN MARKETS
    • U.S. MARKETS
    • COMMODITIES
    • EMERGING MARKETS
    • DEALS
    • RATES & BONDS
  • WORLD
    • UNITED STATES
    • EUROPE
    • UNITED KINGDOM
    • ASIA PACIFIC
    • MIDDLE EAST
    • AFRICA
    • CHINA
    • INDIA
    • JAPAN
    • AMERICAS
    • FRANCE
    • GERMANY
  • POLITICS
    • GOVERNMENT
    • UNITED STATES
    • US SUPREME COURT
  • TECH
    • ARTIFICIAL INTELLIGENCE
    • CYBERSECURITY
    • SPACE
    • DISRUPTED
  • COMMENTARY
  • BREAKINGVIEWS
    • BREAKINGVIEWS PREDICTIONS
  • MONEY
    • WEALTH
    • FUNDS
    • ETFS
  • LIFE
    • LIFESTYLE
    • SPORTS
    • SCIENCE
  • SECTORS
    • ENERGY
    • HEALTHCARE
    • MEDIA & TELECOM
    • SUSTAINABILITY
    • ENVIRONMENT
    • RETAIL & CONSUMER
    • AUTOS & TRANSPORTATION
    • AEROSPACE AND DEFENSE
FinanceTime
  • August 20th, 2026

FinanceTimeFinancetime

  • BUSINESS
    • FINANCE
    • LEGAL
    • RETAIL & CONSUMER
    • AUTOS & TRANSPORTATION
    • HEALTHCARE & PHARMACEUTICALS
    • MEDIA & TELECOM
    • AEROSPACE AND DEFENSE
    • ENERGY
  • MARKETS
    • EUROPEAN MARKETS
    • ASIAN MARKETS
    • U.S. MARKETS
    • COMMODITIES
    • EMERGING MARKETS
    • DEALS
    • RATES & BONDS
  • WORLD
    • UNITED STATES
    • EUROPE
    • UNITED KINGDOM
    • ASIA PACIFIC
    • MIDDLE EAST
    • AFRICA
    • CHINA
    • INDIA
    • JAPAN
    • AMERICAS
    • FRANCE
    • GERMANY
  • POLITICS
    • GOVERNMENT
    • UNITED STATES
    • US SUPREME COURT
  • TECH
    • ARTIFICIAL INTELLIGENCE
    • CYBERSECURITY
    • SPACE
    • DISRUPTED
  • COMMENTARY
  • BREAKINGVIEWS
    • BREAKINGVIEWS PREDICTIONS
  • MONEY
    • WEALTH
    • FUNDS
    • ETFS
  • LIFE
    • LIFESTYLE
    • SPORTS
    • SCIENCE
  • SECTORS
    • ENERGY
    • HEALTHCARE
    • MEDIA & TELECOM
    • SUSTAINABILITY
    • ENVIRONMENT
    • RETAIL & CONSUMER
    • AUTOS & TRANSPORTATION
    • AEROSPACE AND DEFENSE
A 0.25 mg injection pen of Novo Nordisk's weight-loss drug Wegovy is shown in this photo illustration in Oslo, Norway, August31, 2023. Victoria Klesty/Illustration/file photo
A 0.25 mg injection pen of Novo Nordisk's weight-loss drug Wegovy is shown in this photo illustration in Oslo, Norway, August31, 2023. Victoria Klesty/Illustration/file photo
Home
Business
Healthcare & Pharmaceuticals

Novo's Wegovy weight-loss drug will cost 199-299 pounds in UK -Simple Online Pharmacy

September 4th, 2023 | 08:35 AM BUSINESS Healthcare & Pharmaceuticals 1

Facebook Twitter Google+ LinkedIn Pinterest

Worth reading...

Multistate salmonella infections climb to 431, US CDC says
Ultragenyx's gene therapy wins first FDA approval for rare metabolic disorder
Michigan confirms human case of rare mosquito-borne disease
US FDA approves Regeneron's rare bone disorder drug
By Reuters

Simple Online Pharmacy, a UK-based online pharmacy chain, told Reuters on Monday that it would sell Novo Nordisk's (NOVOb.CO) weight-loss drug Wegovy in the range of 199 pounds to 299 pounds ($251-$377).

It was the first indication from a pharmacy of how much the popular drug would cost in Britain after Novo announced it had launched Wegovy earlier on Monday.

(This story has been officially corrected to show price starting from 199 pounds, not 149 pounds)

($1 = 0.7921 pounds)

($1 = 0.7920 pounds)

  • Topic
  • HEALTH
  • OBESITY/NOVO NORDISK
  • PHARMACY (CORRECTED, URGENT)
Facebook Twitter Google+ LinkedIn Pinterest
Previous article Multistate salmonella infections climb to 431, US CDC says

Related Posts

Healthcare & Pharmaceuticals
August 19th, 2026

Multistate salmonella infections climb to 431, US CDC says

Healthcare & Pharmaceuticals
August 19th, 2026

Ultragenyx's gene therapy wins first FDA approval for rare metabolic dis...

Healthcare & Pharmaceuticals
August 19th, 2026

Michigan confirms human case of rare mosquito-borne disease

Healthcare & Pharmaceuticals
August 19th, 2026

US FDA approves Regeneron's rare bone disorder drug

Healthcare & Pharmaceuticals
August 19th, 2026

West Nile virus outbreak kills four in North Macedonia 

Healthcare & Pharmaceuticals
August 19th, 2026

Moderna shares double as cancer vaccine data rekindles investor hopes

The Wire
Aug 20th 3 h ago
Investigates

In China, rocket launches fuel tourism and space-age dreams

Aug 19th 4 h ago
Asia Pacific

Japan exports rise 23.2% year/year in July

Aug 19th 4 h ago
Baseball

D-backs score twice in 10th, salvage series finale at Red S...

Aug 19th 5 h ago
Government

US tells schools not to alter discipline policies to reduce...

Aug 19th 5 h ago
Transactional

China tax crackdown forces wealthy investors to assess thei...

TRENDING ON FINANCETIME
Aug 19th, 2026 Tennis

Paul ousts top seed Zverev to reach Cincinnati quarter-finals

Aug 19th, 2026 Litigation

AIA Group's first-half new business value rises 10%

Aug 19th, 2026 Energy

Brazil's largest thermal power plant shut down after equipment failure

Aug 19th, 2026 United Kingdom

Key moments in Prince Harry and Meghan's six years in California

Aug 19th, 2026 Sports

Orioles reinstate C Samuel Basallo (shoulder) to active roster

Markets-Sectors
ENERGY -0.16%
FINANCIALS -0.62%

  • BUSINESS
  • MARKETS
  • WORLD
  • POLITICS
  • TECH
  • COMMENTARY
  • BREAKINGVIEWS
  • MONEY
  • LIFE
  • SECTORS
  • Back to top
FinanceTime
FinanceTime

World Business & Financial News, Breaking US & International News

Additional Services
  • Privacy-Policy
  • Terms and Conditions
© Financetime.org 2026. All rights reserved. Hosted by LeadsDeposit.com
Produced by C-iT